Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of IPN01203 in advanced solid tumors after immune checkpoint inhibitor therapy
2025-522184-15-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- Feb 2026
- Countries
- 2
01
Overview
Phase 2, open-label trial of IPN01203 in Nonhematologic neoplasms (2 arms), sponsored by Ipsen. Primary endpoints: Percentage of participants with dose limiting toxicity, Treatment-emergent adverse events and serious adverse events and 1 more. Planned start Feb 2026; status: authorised.
02
Drugs
IPN01203
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-522184-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522184-15-00.